LMY-920 not checked

Luminary Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“Single infusion of 4×10\^6 cells/kg of LMY-920 (autologous CAR-T cell therapy expressing the BAFF-ligand.)”In the company’s words, NCT07771361 on ClinicalTrials.gov
Tested for
Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma in Remission and 1 more
Main trialPhase 2
“Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.”In the company’s words, NCT07771361 on ClinicalTrials.gov
Other names
BAFF CAR-T

Other drugs for Non-Hodgkin Lymphoma Refractory/ Relapsed

All 166 drugs for Non-Hodgkin Lymphoma Refractory/ Relapsed

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Dec 2030 BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Phase 1Recruiting 15 Apr 2026 BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Phase 1Unknown 1 May 2025 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LMY-920

Following is part of Solo: you see every change to LMY-920 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in